5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS Russian patent published in 2024 - IPC C07D211/08 C07D491/107 A61P25/28 A61K31/397 A61K31/435 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, where R¹ is halogen or hydrogen; R² is halogen or hydrogen; R³ is optionally substituted C_1-3alkyl, wherein said alkyl is optionally substituted with tetrahydropyranyl, optionally substituted 5–6 membered heteroaryl selected from the group consisting of pyrimidinyl, 1,3,4-oxadiazolyl and oxazolyl, wherein said heteroaryl is optionally substituted with one C_1-3alkyl, optionally substituted 4–6 membered heterocycloalkyl selected from the group consisting of tetrahydrofuranyl and tetrahydropyranyl, wherein said heterocycloalkyl is optionally substituted with one -OH, optionally substituted 4–6 membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one -OH; or -OR⁴; R⁴ is optionally substituted C_1-5alkyl, wherein said alkyl is optionally substituted with one or two R⁶, optionally substituted 3–9 membered heterocycloalkyl selected from the group consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxanyl and 2-oxaspiro[3.3]heptanyl, wherein said heterocycloalkyl is optionally substituted with one or two R⁶, or optionally substituted 4–6 membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one, two or three R⁶; R⁵ is halogen or hydrogen; each R⁶ independently represents a halogen, -OH, -OCH₃, -C(CH₃)₂OH, -CH₂OH, cyano, optionally substituted C_1-4alkyl, wherein said alkyl is optionally substituted with -OH, optionally substituted 4–7 membered heterocycloalkyl, selected from the group consisting of tetrahydrofuranyl, 1,4-dioxanyl, tetrahydropyranyl, oxetanyl, 2-oxaspiro[3.3]heptanyl and 3-oxabicyclo[3.1.0]hexanyl, wherein said heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of halogen, -OH, -OCH₃ and C_1-3 alkyl, or optionally substituted 5–6 membered heteroaryl selected from the group consisting of 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, pyrimidinyl and 1,2,4-oxadiazolyl, wherein said heteroaryl is optionally substituted with one C_1-3alkyl; and R⁷ is 5-membered heteroaryl selected from the group consisting of 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl and 1,2,4-oxadiazolyl. Invention also relates to a pharmaceutical composition containing a compound of formula (I) and to the use of the compound of formula (I) for the treatment of psychosis associated with schizophrenia, schizoaffective disorder, psychotic depression, bipolar disorder with psychotic features, Alzheimer's disease or frontotemporal dementia.

EFFECT: compound of formula (I) used as an M4 receptor agonist.

24 cl, 3 dwg, 122 ex, 12 tbl